COVID-19-driven endothelial damage: complement, HIF-1, and ABL2 are potential pathways of damage and targets for cure
Monia Marchetti
Topics & Concepts
MedicineEculizumabHematologyHypoxia (environmental)ImatinibImmunologyCoronavirus disease 2019 (COVID-19)Endothelial dysfunctionClinical trialTyrosine kinaseInflammationComplement systemIntensive care medicineBioinformaticsInternal medicineBiologyDiseaseInfectious disease (medical specialty)ReceptorImmune systemMyeloid leukemiaChemistryOxygenOrganic chemistryComplement system in diseasesCOVID-19 Clinical Research StudiesPlatelet Disorders and Treatments